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Abstract
Background: Macrophages play an important role in the inflammatory responses involved with spinal cord injury
(SCI). We have previously demonstrated that infiltrated bone marrow-derived macrophages (BMDMs) engulf myelin
debris, forming myelin-laden macrophages (mye-Mϕ). These mye-Mϕ promote disease progression through their
pro-inflammatory phenotype, enhanced neurotoxicity, and impaired phagocytic capacity for apoptotic cells.
We thus hypothesize that the excessive accumulation of mye-Mϕ is the root of secondary injury, and that
targeting mye-Mϕ represents an efficient strategy to improve the local inflammatory microenvironment in
injured spinal cords and to further motor neuron function recovery. In this study, we administer murine embryonic
stem cell conditioned media (ESC-M) as a cell-free stem cell based therapy to treat a mouse model of SCI.
Results: We showed that BMDMs, but not microglial cells, engulf myelin debris generated at the injury site.
Phagocytosis of myelin debris leads to the formation of mye-Mϕ in the injured spinal cord, which are surrounded by
activated microglia cells. These mye-Mϕ are pro-inflammatory and lose the normal macrophage phagocytic capacity
for apoptotic cells. We therefore focus on how to trigger lipid efflux from mye-Mϕ and thus restore their function.
Using ESC-M as an immune modulating treatment for inflammatory damage after SCI, we rescued mye-Mϕ function
and improved functional locomotor recovery. ESC-M treatment on mye-Mϕ resulted in improved exocytosis
of internalized lipids and a normal capacity for apoptotic cell phagocytosis. Furthermore, when ESC-M was
administered intraperitoneally after SCI, animals exhibited significant improvements in locomotor recovery.
Examination of spinal cords of the ESC-M treated mice revealed similar improvements in macrophage
function as well as a shift towards a more anti-inflammatory environment at the lesion and parenchyma.
Conclusions: The embryonic stem cell conditioned media can be used as an effective treatment for SCI to
resolve inflammation and improve functional recovery while circumventing the complications involved in
whole cell transplantation.
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Background
Spinal cord injury (SCI) results in a debilitating chronic
condition, complicated by costly and complex rehabilita-
tion challenges [1]. The pathophysiology of an acute SCI
comprises both primary and secondary mechanisms of in-
jury [2]. The primary injury, resulting from mechanical
trauma to the spinal cord, leads to immediate vasospasm
of the superficial vessels and intraparenchymal hemorrhage
[3]. The culmination of the events of the acute primary
injury stage initiates the secondary injury cascade. The
secondary injury is characterized by a prolonged inflam-
matory response [4, 5], resulting in further tissue
damage and neurodegeneration by resident microglia
and infiltrated bone marrow-derived macrophages
(BMDMs) [6].
In the spinal cord, the clearance of apoptotic cells
and myelin debris is the responsibility of infiltrating
macrophages, and to a lesser degree, resident micro-
glia. The myelin debris contains a variety of myelin-
associated inhibitors of axonal regeneration including
Nogo-A, myelin-associated glycoprotein (MAG) and
myelin-oligodendrocyte glycoprotein (MOG) [7]. Add-
itionally, large numbers of circulating neutrophils in-
filtrate in the first day after injury [8] where they are
frequently present in the injury site for more than
40 days [9]. If apoptotic neutrophils can’t be effi-
ciently cleared by macrophages from injury site, these
uningested apoptotic neutrophils undergo secondary
necrosis and it is inevitable that there is an uncon-
trolled release of toxic intracellular contents from
necrotic neutrophils into the tissue where it causes
further damage [10]. Thus, prompt clearance of the
array of apoptotic cells and myelin debris by macro-
phages is critical to limit the inflammatory cascade
and promote neuroregeneration [8].
Along with the cell debris generated following SCI,
there is also dramatic accumulation of lipids derived
from myelin debris in the lesion extending far beyond
the epicenter [11, 12]. Persistence of these lipids is part
of the chronic pathology and results in lipid peroxida-
tion, one of the most damaging side-effects of lipid re-
tention. Lipid homeostasis in the injured spinal cord is
highly dysregulated, leading to the formation of persist-
ent foamy lipid laden macrophages. Our previous studies
have demonstrated the pro-inflammatory characteristics
of these foamy macrophages, which include but are not
limited to enhanced neurotoxicity, and impaired wound
healing [8]. Here we have shown that dysregulation of
macrophage lipid homeostasis in the injured cord, is the
major contributing factor of long term lipid retention.
We propose that these pro-inflammatory myelin-laden
macrophages (mye-Mϕ) are an important therapeutic
target in SCI because of their reduced ability to clear
apoptotic cells and myelin debris at the injury site.
Embryonic stem cells (ESCs) have shown therapeutic
potential to remyelinate axons as ESC derived oligo-
dendrocyte precursor cells (OPCs) can generate func-
tional myelin in situ [13]. Their application in SCI
though may have limited success due to the risk of
tumor formation after transplantation and immune re-
jection [14, 15]. Our previous studies have shown that
ESCs produce factors can induce anti-inflammatory
phenotype in macrophages [16, 17]. Upon ESC stimula-
tion, phagocytic function was enhanced and macro-
phages expressed multiple angiogenic growth factors
and proteinases promoting angiogenesis [16, 17]. These
properties correspond with the characteristics required
for successful treatment for SCI pathology, driving us to
investigate the novel application of ESC derived factors
for treating inflammation in acute murine SCI.
Results
Myelin-laden macrophages in vivo and in vitro
Myelin debris persists for extended periods of time in
the injured spinal cord [18, 19], where it is retained
intracellularly by macrophages. We have previously
demonstrated that infiltrated bone marrow-derived
macrophages (BMDMs) migrate to the epicenter of the
injured spinal cord. In the injury site, they phagocytose
myelin debris leading to the formation of myelin-laden
macrophages (mye-Mϕ) which are distinguished as Oil
Red O (ORO) positive cells [8]. These mye-Mϕ take on
a foamy appearance due to the large number of intra-
cellular lipid droplets, and are a hallmark of phagocytic
activity in atherosclerosis [20] and demyelinating dis-
eases such as experimental allergic encephalomyelitis
(EAE) and multiple sclerosis (MS) [21]. ORO selectively
stains intracellular neutral lipids such as cholesterol
ester (CE) but not intact myelin in the normal central
nervous system (CNS) and peripheral nervous system
(PNS). ORO-positive lesions reveal foamy cell accumu-
lation in the injury site. Figure 1a shows high intensity
ORO staining localized to the lesion epicenter at
2 weeks post-SCI. Using electron microscopy, we find
lipid droplets (arrows) in the cytoplasm of the mye-Mϕ
at the injury site. At 10 days post-SCI, the small evenly
distributed morphology of the droplets is comparable
to those observed in vitro. At 10 weeks, there is a no-
ticeable decrease in the number of intracellular lipid
droplets as well as an increase in the size per droplet.
The trend towards fewer and larger droplets continues
up to 18 weeks post-SCI, at which point a single droplet
per cell can be observed (Fig. 1b). The same lipid accu-
mulation is observed in vitro when BMDMs are incu-
bated in the presence of myelin debris as demonstrated
by F4/80+ mye-Mϕ with small lipid droplets distributed
throughout the cytoplasm (Fig. 1c).
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BMDMs are the primary myelin phagocytosing cells in SCI
As both macrophages and their nervous system counter-
parts, microglia, are considered professional phagocytes
[22], we sought to address their individual contribution
in the lipid laden at injury epicenter. We implemented a
CX3CR1GFP/+ transgenic mouse in which all microglial
cells express strongly GFP, while BMDMs are weakly
positive [8]. As early as 3 days, ORO staining revealed
intracellular lipid accumulation at the injury site. How-
ever, little to no lipid staining was detected within
CX3CR1+ cells, indicating that myelin phagocytosis was
carried out almost entirely by infiltrated BMDMs, not by
microglial cells (Fig. 2a). This pattern of lipid localization
is observed at 1 week and 2 weeks, with an increasing
lack of ORO signal co-localization in the microglia
(Fig. 2a). Six weeks post SCI, microglia are excluded
from the injury epicenter where the high intensity ORO
staining is present along with BMDMs (Fig. 2b). In order
to confirm the BMDMs are the major myelin debris
scavenger cells in SCI, tissue sections were stained with
F4/80, a membrane protein expressed on macrophages
and microglia. BMDMs are F4/80+++/CX3CR1−/±, while
microglia are F4/80+++/CX3CR1+++. This aided to fur-
ther clarify that the lipids are intracellular and co-
localize with BMDMs (yellow arrows) more frequently
than microglia (red arrows) (Fig. 2c). While a major
Fig. 1 Mye-Mϕ formation in vivo and in vitro. a Using Oil Red O (ORO) staining, lipid accumulation at the injury site can be observed starting as
diffuse staining at 10 days and by 2 weeks after SCI. There is a central core of high intensity staining at 2 weeks post SCI. b Electron micrographs
of macrophages in the injured spinal cord at indicated time points. c In vitro induction of mye-Mϕ. BMDMs (F4/80+) incubated with myelin debris
and intracellular lipids were labeled by ORO. 3D reconstruction by confocal microscopy shows the myelin-derived lipids distributed throughout the
cell subsequent to myelin treatment (right)
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function of both BMDMs and microglia is phagocytosis,
astrocytes are also known to have a limited capacity to
clear debris in neurodegenerative disease states [22]. To
further validate that BMDMs are the primary cells re-
sponsible for engulfing myelin debris, quantification of
the myelin phagocytic capacity of BMDMs, microglia,
and astrocytes was performed. Myelin debris was incu-
bated with primary cultures of the three of cell types for
the indicated time, at which point the intracellular mye-
lin basic protein (MBP) was determined. Microglial cells
showed a moderate ability to engulf myelin but it was
significantly less than BMDMs. Unsurprisingly, the con-
tribution of the astrocytes to the myelin debris phagocyt-
osis was exceedingly low (Fig. 2d).
Consequences of impaired mye-Mϕ phagocytosis in the
injured spinal cord
Neutrophils play an important role in inflammation
initiation and resolution. In the case of non-resolving
inflammation, neutrophils persist at the inflamed site
where they can cause additional tissue destruction
[23, 24]. Moreover, the removal of neutrophils and
their potentially histotoxic contents is a prerequisite
of inflammation resolution [25, 26]. Given that our previ-
ous in vitro data revealed mye-Mϕ have a reduced effero-
cytosis capacity [8], we hypothesized that there is a
prolonged accumulation of neutrophils in injured spinal
cord from mye-Mϕs failing to clear them. At 5 days post-
SCI, neutrophils can still be observed in the injury site
Fig. 2 Macrophages are the Primary Myelin Phagocytosing Cells in SCI. Using a CX3CR1GFP/+ transgenic mouse model of SCI, tissue sections were
stained with ORO to show the localization of lipids within cells after injury. a The distribution of lipid droplets in CX3CR1 strongly positive cells
(microglia, CX3CR1+++) and weakly positive or negative cells (BMDMs, CX3CR1-/±) at the lesion sites at different time points after SCI. b Imaging of
the entire injury site at 6 weeks shows the progressive exclusion of microglia (CX3CR1+++) from epicenter where the majority of the lipids are
retained. c Staining of F4/80 provides clear cell membrane boundaries to further validate the localization of the lipids predominantly within the
BMDMs (F4/80+CX3CR1-/±, yellow arrows) with less being localized to the microglia (F4/80+CX3CR1+++, red arrows). d Quantification of myelin debris
phagocytosis in BMDMs, astrocyte, and microglia by detecting intracellular MBP by ELISA (n = 3). (*p < 0.05) Data are represented as means ± SD
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along with BMDMs (Mac-2, the marker for BMDMs
[8]). Of the neutrophils present, few co-localized with
BMDMs, consistent with a lack of phagocytosis
(Fig. 3). Up to 2 weeks post SCI, neutrophils are still
observed in the lesion outside of macrophages indi-
cating a lack of clearance.
ESC-M regulates inflammatory response
We previously demonstrated myelin debris is a potent
pro-inflammatory stimulus that inhibits M2-like
macrophage activation and enhances expression of
pro-inflammatory cytokines such as tumor necrosis
factor-α (TNF-α) [8, 12]. We also showed that ESCs
are able to polarize BMDMs into M2-like macro-
phages [16, 17], thus we reasoned that ESCs may
have anti-inflammatory properties. To explore the po-
tentially anti-inflammatory effects of ESCs on mye-
Mϕ, we used ESC conditioned media (ESC-M) as a
cell-free treatment. BMDMs were cultured with mye-
lin debris for 24 h to induce mye-Mϕ and then
treated with CON-M or ESC-M for 24 h prior to lysis
and RNA extraction. ESC-M treatment significantly
reduced TNF-α expression in mye-Mϕ compared to
CON-M treated mye-Mϕ (Fig. 4a). Not only did ESC-M
decrease pro-inflammatory TNF-α transcription, it also
significantly increased expression of arginase-1 (Arg-1),
the well-documented M2 marker, compared to CON-M
treated mye-Mϕ (Fig. 4a). These data suggests that ESCs
produce factors which may directly augment the inflam-
matory response by regulating myelin-induced macro-
phage activation.
ESC-M enhances myelin debris clearance and rescues
impaired mye-Mϕ phagocytic capacity for apoptotic cells
Myelin debris removal and apoptotic cell clearance are
critical for axon remyelination and resolution of inflam-
mation, making them important therapeutic targets. To
test if ESC-M would be useful for this application as
well, BMDMs were treated with CON-M and ESC-M for
24 h then incubated with myelin debris for 1 or 2 h.
Visually, ORO staining revealed large amounts of intra-
cellular lipids associated with each cell in the ESC-M
treated group indicating high levels of phagocytosis
(Fig. 4b). MBP ELISA confirmed ESC-M treated cells
contained significantly higher amounts of intracellular
MBP than CON-M at 2 h which is correlated to
Fig. 3 Neutrophil accumulation at the injured spinal cord. a Immunohistochemical analysis showing neutrophils (Gr-1+, red) at the lesion site at
indicated time after SCI. Infiltrated BMDMs were labeled by Mac-2 antibody (green). b Quantification of neutrophil infiltration at the injury
site (n = 3). Data are represented as means ± SD
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increased phagocytosis of myelin debris (Fig. 4b). To as-
sess the phagocytosis of apoptotic cells in response to
ESC-M, BMDMs were incubated with myelin debris for
24 h to induce mye-Mϕ, then incubated in ESC-M or
CON-M for an additional 24 h. Apoptotic cells labeled
with CFSE were then added to macrophages at a con-
centration of 10:1 for 30 min. Non-phagocytosed cells
were washed away and macrophages containing CFSE
positive cells were quantified (Fig. 4c). The phagocytosis
of apoptotic cells in mye-Mϕ is significantly inhibited
but, ESC-M treatment rescued the impaired phagocyt-
osis of the mye-Mϕ (Fig 4c). These results represent a
novel function for ESC secreted factors to enhance the
phagocytosis of myelin debris and rescue the mye-Mϕ
clearance of apoptotic cells.
ESC-M enhances lipid efflux from mye-Mϕ reducing the
formation of foamy cells
Because the ESC-M treated mye-Mϕ showed increased
myelin debris engulfment and normal apoptotic cell
phagocytosis, we reasoned that this was related to the
rescued efflux capacity of intracellular lipids. To test if
ESC-M is also able to increase reverse cholesterol trans-
port, BMDMs were loaded with myelin debris for 2 h
and undigested myelin debris was washed away. Staining
with ORO revealed neutral lipid droplets localized to the
Fig. 4 The effects of ESC-M on regulation of macrophage activation and phagocytosis. a BMDMs were incubated with myelin debris to induce
mye-Mϕ, and then incubated with CON-M or ESC-M for 24 h respectively. The mRNA levels of TNF-α and arginase-1 (Arg-1) were determined by
RT-PCR (n = 4). Fold change values were normalized to mye-Mϕ treated with CON-M. b BMDMs were pre-treated with CON-M or ESC-M for 24 h
and then incubated with myelin debris for 1 or 2 h. The myelin lipids engulfed were stained by ORO (left, original magnification, ×200). Intracellular
MBP was assayed by ELISA to determine the quantity of phagocytosed myelin debris (right, n = 3). c Naïve-Mϕ (BMDMs without myelin treatment) or
mye-Mϕ were treated with CON-M or ESC-M for 24 h and then incubated with apoptotic thymocytes labeled with CFSE for 30 min to test apoptotic
cell phagocytosis (left, original magnification, ×200). The percentage of ingested apoptotic cells were calculated (right, n = 4). (*p < 0.05)
Data are represented as means ± SD
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periphery of the cell membrane in the ESC-M treated
cells and a diffuse pattern in CON-M cells. The
localization of lipids to the periphery is a prerequisite for
efflux (Fig 5a). This staining pattern was defined ring
cells and the percentage of cells that exhibited this ar-
rangement was quantified. At all time points, the ESC-
M enhanced lipid droplet trafficking to the cell periphery
(Fig. 5b). To confirm that the peripheral lipids in the
ring cells were in fact exocytosed lipids, free cholesterol
in the culture media was assayed. Once again, at all time
points the ESC-M showed enhanced cholesterol efflux
as measured by free cholesterol concentrations (Fig. 5c).
The major cholesterol efflux transporters in macro-
phages are the ATP-binding cassette family members,
ABCA1 and ABCG1 [27]. Western blotting for these
transporters in macrophages indicated that ESC-M en-
hances the expression of both transporters compared to
CON-M. In both media treatments, the addition of
myelin debris increased transporter expression as ex-
pected, although the ESC-M with myelin treatment
showed still a larger increase than CON-M with myelin
(Fig 5d). This observation represents a novel function of
ESCs to trigger lipid efflux from foam cells.
ESC-M improves locomotor recovery
To test whether improved macrophage function could
be enhanced in an acute SCI model, one mL of ESC-M
or CON-M was injected intraperitoneally (i.p.) immedi-
ately after the surgery and every 3 subsequent days. To
assess the ability of this treatment method to improve
functional outcomes, we implemented three measures of
locomotor activity, the BMS scale [28], regained coord-
ination [29], and the horizontal ladder beam test [30].
Comparing to CON-M group, BMS scores of the ESC-
M group were significantly higher (ANOVA, p <0.05)
after the first day. At 7 weeks post-injury (termination of
Fig. 5 ESC-M Enhances Lipid Efflux from Mye-Mϕ Reducing the Formation of Foamy Cells. a BMDMs exocytosing lipids can be visualized with a
ring of lipid droplets (ring cells) on the cell periphery. b Mye-Mϕ were treated with CON-M and ESC-M, respectively for indicated time points. The
number of foam cells exocytosing lipids was quantified as the percentage of total cells with ring cells (n = 5). c The product of reverse
cholesterol transport is free extracellular cholesterol which was quantified with a flourometric assay (n = 4). d Naïve-Mϕ and mye-Mϕ were
incubated with CON-M and ESC-M for 24 h. The expression of ABCA1 and ABCG1 were determined by Western Blot. (*p < 0.05) Data are represented
as means ± SD
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the study) the average BMS scores per group were: ESC-
M (n = 25) 6.3, CON-M (n = 17) 5.1 (Fig. 6a). These
scores corresponded to the improvement in the fre-
quency of coordination test for ESC-M vs. CON-M
groups. We used Chi-squared frequency analysis to
compare the percentage of mice in each group that had
regained at least occasional coordination in the loco-
motor assessment. Recovery of coordination was signifi-
cantly increased in ESC-M group (96 %) compared to
CON-M group (20 %) (Fig. 6b). Additionally, the hori-
zontal ladder beam task suggested that ESC-M treated
mice exhibited significantly fewer errors than CON-M
treated mice (Fig. 6c).
ESC-M reduces lipid accumulation and regulates the
inflammatory response in the injured spinal cord
As in vitro phagocytosis assays had already shown
rescued phagocytic capacity following ESC-M treat-
ment, we sought to assess this effect in vivo. Staining
for Gr-1 was performed to determine the ability of
ESC-M treated animals to clear neutrophils, a critical
step in termination of the inflammatory cascade [10].
After one week, no difference in neutrophil accumu-
lation is present, but at two weeks post-SCI fewer
neutrophils are present in the injury site of ESC-M
treated group compared to CON-M treated group
(Fig. 6d). We also investigated lipid accumulation in
Fig. 6 ESC-M Reduces Lipid and Neutrophil Accumulation and Improves Locomotor Recovery. SCI mice were injected (i.p.) with ESC-M (n = 25)
or CON-M (n = 17) (1 mL per mouse) after surgery and every 3rd subsequent day. a The locomotor function was assessed by Basso Mouse Scale
(BMS) (ANOVA, p < 0.05). b Recovery of coordination in CON-M and ESC-M treated mice using chi square analysis for observed frequency. c The
alternative horizontal ladder beam coordination based measure of locomotor activity on mice treated with CON-M or ESC-M. d Neutrophil
accumulation was determined by detecting Gr-1+ cells in SCI mice treated with CON-M and ESC-M for 1 and 2 weeks (n = 4). e Lipid accumulation
was determined by ORO staining in SCI mice treated with CON-M and ESC-M for 3 weeks (n = 4). (*p < 0.05) Data are represented as means ± SD
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the injury because our in vitro results had demon-
strated improved resolution of foamy cells through
enhanced ABCA1 expression following ESC-M treat-
ment. Using ORO staining, at 3 weeks post-SCI the
accumulated lipid area of ESC-M group was signifi-
cantly less than CON-M group (Fig 6e). This suggests
that the effects ESC-M has in vitro on rescued
phagocytosis and lipid efflux are also present in vivo
and correlated to improved functional recovery.
To determine if the improved recovery correlated with
decreased inflammation in the injured spinal cord, we
examined the expression of several macrophage activa-
tion markers (Fig. 7a). Although ESC-M treatment did
not decrease iNOS expression at the injury site, it did
significantly increase Arg-1 expression with no change
in the number of macrophages at the injury site between
groups at 1 week post-SCI (Fig. 7a, b). Because mye-Mϕ
have M1-like phenotype [8], our current results suggest
that ESC-M treatment may be able to promote the
transition of mye-Mϕ from a M1-like to M2-like
polarization. Furthermore, it is important to note that
the ESC-M treatment does not alter macrophage recruit-
ment to the injury as their role in debris clearance seems
critical in promoting functional recovery.
Discussion
Embryonic stem cell therapies have shown promising
clinical applications for various conditions, but they are
not without serious ethical and technical limitations.
One such technical hurdle that must be overcome is
mitigating the risk of teratoma formation associated with
ESC derived grafts. To address the possibility of tera-
toma development, various risk reducing strategies have
been developed such as prolonged pre-differentiation
in vitro, blocking of proliferative signaling pathways,
inducing proliferative ESC apoptosis, sorting cells ex-
pressing precursor markers, and deleting undifferenti-
ated ESCs [31–42]. However, it should be noted that it is
Fig. 7 In vivo anti-inflammatory response elicited by ESC-M. a Representative images of spinal sections 1 week after injury with double-staining
for F4/80/Agr-1 or F4/80/iNOS in CON-M and ESC-M treated mice. b The Arg-1 and iNOS expression were quantified by Image Pro Plus 6 (n = 3).
(*p < 0.05) Data are represented as means ± SD
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challenging to obtain a pure culture for safe transplant-
ation, and the contamination of grafts with undifferenti-
ated cells dramatically increases the likelihood of
teratoma formation [14, 15, 43]. The method of ESC-M
treatment presented here represents a novel therapy
which circumvents many of the traditional limitations of
ESCs based treatments. Systemic delivery of the treat-
ment can be performed with no observed side-effects
and the risk for immune rejection and tumor formation
are eliminated. Additionally, application of the ESC
secretome independent of whole cells reduces the need
for embryonic tissue collection and the ethical concerns
associated with obtaining it. In our previous study, we
showed that ESCs secrete a combination of molecules,
including molecules that recruit macrophages, such as
VEGF, MMP-9 and MCP-1 [17]. Also secreted by ESCs
are molecules that promote macrophage survival and
polarize macrophages towards a M2-like phenotype,
such as IL-34 [16]. Moreover, it is also not unreasonable
to suggest that if the specific secreted factors regulating
recovery can be identified, human therapies could be de-
veloped which do not depend on the direct culture of
ESCs.
In the present study, we have established a novel appli-
cation for ESC conditioned media to rescue mye-Mϕ
function and promote recovery in a murine SCI model.
The ESC-M induced effects can be best characterized as
M2-like due to increased Arg-1 expressed in the lesion
concurrent with other signs of injury resolution like re-
duced lipid and neutrophil accumulation. ESC-M treat-
ment can also be considered inflammation reducing as it
decreased the expression of TNF-α, a pleotropic cyto-
kine produced by monocytic linage cells. This is of par-
ticular significance because TNF-α is considered a
master-regulator in chronic inflammatory conditions
[44] and is a known regulator of macrophage apoptotic
cell efferocytosis [45]. It has also been demonstrated that
TNF-α prevents mye-Mϕ conversion from M1-like to
M2-like macrophages in vitro and in vivo [46]. The re-
duced TNF-α therefor represents a possible mechanism
for the observed increase in Arg-1, as well as improved
cell debris clearance in ESC-M treated animals.
Our previous studies have demonstrated the pro-
inflammatory nature of mye-Mϕ and their deleterious
role in SCI [8]. Here we also examined the role of resi-
dent microglia as they are from the same monocytic
lineage and are responsive to similar stimuli. Three in-
dependent microscopic methods indicate the intracellu-
lar lipids are predominantly localized with BMDMs,
despite ability of microglia to likewise phagocytose cell
debris. Further quantification of intracellular MBP sup-
ported the establishment of BMDMs as the primary
myelin phagocytosing cell type with microglia and as-
trocytes having a lesser role. Because microglia have a
weaker phagocytic capacity for myelin debris and are
progressively excluded from the epicenter over time,
our conclusion that BMDMs are the primary foamy
cells was further supported.
The persistence of foamy mye-Mϕ in the injured cord,
we reasoned, also had the potential to be mitigated by
ESC-M treatment. Macrophages normally efflux intra-
cellular lipids to cholesterol poor proteins in the blood
[20] through ABCA1 and ABCG1 [47], but in the in-
jured spinal cord ABCA1 expression is dramatically re-
duced [8]. This implicates ABCA1 reduction as a driver
of foam cell formation. Upon ESC-M treatment, en-
hanced the expression of both transporters is induced as
well as increased lipid exocytosis and resolution of the
lipid rich injury epicenter. It could be argued that the
less lipid-laden macrophages could be the result of fewer
macrophages or decreased myelin phagocytosis. This is
unlikely as there was no significant change in F4/80
positive cells between treatments in vivo and ESC-M sig-
nificantly enhanced myelin phagocytosis and subsequent
exocytosis in vitro.
Conclusion
In conclusion, the present study demonstrates the ap-
plicability of embryonic stem cell conditioned media to
effectively treat SCI by reducing lipid accumulation, pro-
moting a M2-like state and improving functional recov-
ery. This strategy represents a significant paradigm shift
in ESC based therapy, and is one that circumvents the
current complications limiting safe clinical application of
whole cell transplantation. While additional research is
needed to determine the specific factors of the ESC
secretome that induce these changes, we can currently
conclude that ESC-M is sufficient to promote function
recovery in a murine model of SCI.
Methods
Mice strains
C57BL/6, B6.129P-Cx3CR1tm1Litt/J, and B6.Cg-Tg(CAG-
mRFP1)1F1Hadj/J mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and maintained in the
pathogen-free animal facility in Florida State University
College of Medicine. All animal protocols were approved
by the Animal Care and Facilities Committee of Florida
State University.
Reagents and antibodies
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) and cell culture media was purchased from
Invitrogen (Carlsbad, CA) unless specially indicated. The
F4/80 hybridoma cell line is from American Tissue Cul-
ture Collection (ATCC, Manassas, VA, USA). Primary
antibodies included in the study are listed in Table 1.
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Alexa Fluor-conjugated secondary antibodies were pur-
chased from Invitrogen.
Preparation of mouse bone marrow-derived macrophages
Mouse bone marrow-derived macrophages (BMDMs)
were prepared as previously described [17]. Briefly,
bone marrow from 6 to 8 weeks old mice was collected
from femoral shafts by flushing the marrow cavity with
Dulbecco’s modified eagle medium (DMEM) supple-
mented with 1 % fetal bovine serum (FBS). The cell
suspensions were passed through an 18-gage needle to
obtain a single cell suspension. Cells were cultured for
7 days in DMEM supplemented with 15 % conditioned
medium from L929 cells [a source of macrophage
colony-stimulating factor (M-CSF)], 10 % FBS, and 1 %
penicillin/streptomycin (Corning).
Preparation of mouse microglial and astrocyte cultures
Primary astrocyte and microglial cultures were obtained
from C57BL/6 mice between 2 and 3 days old. The cere-
bral cortices were dissected and dissociated prior to plat-
ing in tissue culture flasks. The mixed glial cultures were
grown in DMEM/F12 supplemented with 10 % FBS, and
1 % penicillin/streptomycin (Corning) until reaching
confluence. The flasks were then shaken at 200 rpm for
3 h at 37 °C and microglia in the supernatant were iso-
lated. The cells remaining in the flask after microglia
isolation were cultured as an enriched astrocyte primary
culture [48].
ESC culture and preparation of ESC-conditioned medium
(ESC-M)
The mouse green fluorescent protein (GFP) expressing-
ESC line (F12) derived from a C57BL/6 mouse was
kindly donated by Professor Melitta Schachner (Rutgers
University). As previously described, freshly thawed
ESCs (P0) were seeded into a 100 mm tissue culture
dish with mitomycin-treated murine embryo fibroblasts
(MEFs) as feeder layer. ESC culture medium was com-
posed of 103 U/ml Leukemia Inhibitory Factor (LIF)
(Millipore, CA, USA), 15 % FBS, 1 % non-essential
amino acids solution (MEM), 200 mM L-glutamine, 1 %
nucleoside solution, 1 % 100nM Na-Pyruvate, 0.2 % 2-β-
Mercaptoethanol and DMEM. After 3–4 passages, ESCs
were transferred to a 0.1 % gelatin-coated tissue culture
dish without a feeder layer, and sub-cultured every 2–3
days prior to collection of the conditioned ESC media
(ESC-M). The collected ESC supernatant was spun at
2500 RPM for 10 min and then filtered through a 0.4-
μm filter (Corning, USA) to remove any debris. ESC-M
was collected in this manner from multiple passages and
pooled and stored at −80 °C prior to use. Control culture
medium (without ESCs) was used as control medium
(CON-M) in this study.
Preparation of myelin debris
Myelin debris was isolated from the brains of 3 month
old mice by sucrose density gradient centrifugation, as
described previously [12]. The endotoxin concentration
of myelin debris was under the detection limit of the
Limulus Amebocyte Lysate assay. Myelin debris was
added to cells at a final concentration of 1 mg/mL in all
experiments.
Spinal cord injury
Thoracic spinal cord contusion injuries were performed
on 8–10 weeks old female C57BL/6 mice. The laminec-
tomy was performed to expose the spinal cord at T10.
The contusion injury was induced using the NYU im-
pactor with a 10 g rod dropped 6.25 mm from the cord
surface [49]. Mice contused with asymmetrical injuries
were excluded from experimental analysis.
Treatment groups and basso mouse scale for locomotion
score
One mL ESC-M or CON-M was injected intraperito-
neally (i.p.) per mouse immediately after the surgery
and every 3rd day until the mice were sacrificed.
Basso Mouse Scale (BMS, 0–9) was applied to assess
the locomotor recovery [28] every two days, and the
scores were recorded from the 1 day post-injury until
sacrificed. As a second measure of locomotor activity,
a horizontal ladder beam task was used to measure
coordination [30]. To limit bias, all experiments were
performed double blinded.
Histology and histological staining
Mice were transcardially perfused with 0.9 % saline
followed by 4 % paraformaldehyde. Segments of spinal
cord encompassing the injury site were removed and
post-fixed in 4 % paraformaldehyde overnight at 4 °C
then cryoprotected in 30 % sucrose overnight at 4 °C.
The spinal bones were removed prior to flash freezing in
OTC and slicing into 7 μm-thick parasagittal sections
with a cryostat microtome. For Immunofluorescence
(IF) staining, sections were incubated with 10 mM
Table 1 Primary antibodies
Epitope Catalog Number Manufacturer
ABCA1 89352-256 Genetex
ABCG1 sc-650 Santa Cruz
Arginase-1 4685 Cell Signaling
GAPDH 2118 Cell Signaling
GFAP Z0334 Dako
Gr-1 RB6-8C5 eBioscience
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CuSO4 in 50 mM NH4Ac (pH 5.0; acidified with acetic
acid) for 10 min to reduce autofluorescence after coun-
terstaining with Hoechst [50]. Oil Red O (ORO) staining
was applied to visualize lesion lipid accumulation after
SCI in vivo and macrophages phagocytosing myelin deb-
ris in vitro.
Western blot
After washing with ice-cold PBS, cells were lysed in
RIPA buffer containing a phosphatase inhibitor and pro-
teinase inhibitor cocktail (Amresco). The samples were
adjusted to equal protein concentrations and loaded into
a sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) gel. Proteins on the gel were
transferred to PVDF membranes (GE Healthcare, UK)
and blocked in 5 % milk or BSA (according to antibody
manufacturer’s instructions) in Tris-buffered saline
containing 0.1 % Tween 20 (TBST) for 1 h at RT.
The membranes were incubated with appropriate pri-
mary antibody solution overnight at 4 °C. After rins-
ing in TBST, the membranes were incubated with
appropriate secondary antibody for 1 h. Proteins were
visualized by ECL plus western blot detection system
(GE Healthcare, UK).
RNA isolation and quantitative real-time-PCR
Total RNA was isolated by TRIZOL and reverse-
transcribed into cDNA by using oligo-dT primers and
SuperScript II Reverse Transcriptase. The following pri-
mer pairs of cytokines were specifically designed for
mRNA: TNF-α (5′-GCCTCTTCTCATTCCTGCTTG-3′
and 5′-CTGATGAGAGGGAGGCCATT-3′) and Argi
nase-1 (5′- TTGCGAGACGTAGACCCTGG-3′ and 5′-
CAAAGCTCAGGTGAATCGGC-3′). The ABI7900HT
detection system (Applied Biosystems, UK) was used for
quantitative real-time (qRT)-PCR. SYBR Green dye
(Applied Biosystems) was used to monitor the replica-
tion of PCR products. Quantification of products
were obtained by standard curve and normalized to
GAPDH (5′- ATCAACGACCCCTTCATTGACC-3′
and 5′- CCAGTAGACTCCACGACATACTCAGC-3′)
amount. The gene fold change expression levels were
represented by the ratio of target/GAPDH.
Macrophage apoptotic cell phagocytosis assay
BMDMs were treated with myelin debris for 24 h and
non-ingested myelin debris was washed away. Cells were
then treated with CON-M or ESC-M for 24 h. For the
preparation of apoptotic cells, mouse thymocytes were
incubated with 10 μM dexamethasone at 37 °C for 4 h
[51]. Apoptotic thymocytes were then stained with a
10 μM solution of carboxyfluorescein diacetate succini-
midyl ester (CFSE) to label cells in suspension for
20 min at RT [52], and 5 × 105 cells were added to each
well of macrophages in a 96-well cell culture plate. After
a 30 min interaction at 37 °C in 5 % CO2 atmosphere,
the wells were washed in PBS at 4 °C to remove non-
ingested apoptotic cells. The proportion of macrophages
ingesting at least one thymocyte was counted using
inverted light microscopy [8].
Enzyme-linked immunosorbent assay (ELISA) to detect
myelin debris phagocytosis
Since myelin basic protein (MBP) is a major component
protein of CNS myelin [53], and is not produced by
phagocytes, MBP levels detected in phagocyte cytoplasm
are proportional to levels of myelin debris phagocytosed
[53, 54]. In this study, ELISA for MBP was applied to
study and quantify myelin debris phagocytosis of macro-
phages [55]. In brief, BMDMs were incubated with mye-
lin debris for indicated time. Non-ingested myelin debris
was washed away and intracellular protein was collected
by lysis buffer. The protein concentration of cell lysate
was determined by Pierce BCA Protein Assay Kit
(Thermo Scientific, IL), and 100 μl of coating buffer with
same amount protein per well was loaded into 96-well
plate to coat antigen at 4 °C overnight. Through coating,
blocking, incubating with antibodies and detecting was
performed via standard ELISA procedures.
Analysis of free cholesterol
BMDMs were treated with myelin debris (1 mg/mL) for
24 h at which point undigested myelin was washed away.
Cells were then incubated with CON-M or ESC-M for
additional 3 h, 6 h, 12 h, or 24 h. The supernatant was
collected at the given time points and the free choles-
terol in the supernatant was determined by the enzym-
atic, fluorometric method, using the cholesterol assay kit
(Cayman Chemical, MI).
Statistical analysis
Images were quantified using Image Pro Plus 6 (Media
Cybernetics, USA) and positive signal was reported as
mean signal density. Results showed in figures were pre-
sented as mean ± SD (unless otherwise indicated) with
n representing the number of biological replicates.
Student’s unpaired t-test was used to evaluate statis-
tical significance between two groups and ANOVA
was used for multiple group comparisons. Chi-square
test was used to assess the regained coordination be-
tween treatment groups. A p-value less than 0.05 was
considered significant.
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